248 related articles for article (PubMed ID: 27542243)
1. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.
Fanotto V; Ongaro E; Rihawi K; Avallone A; Silvestris N; Fornaro L; Vasile E; Antonuzzo L; Leone F; Rosati G; Giuliani F; Bordonaro R; Scartozzi M; De Maglio G; Negri FV; Fasola G; Aprile G
Oncotarget; 2016 Oct; 7(42):69060-69074. PubMed ID: 27542243
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma.
Shabbir A; Qureshi MA; Mirza T; Khalid AB
J Pak Med Assoc; 2017 Jul; 67(7):1085-1090. PubMed ID: 28770892
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
Song Y; Huang J; Wang JW
Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
[TBL] [Abstract][Full Text] [Related]
5. Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.
Shabbir A; Mirza T; Khalid AB; Qureshi MA; Asim SA
BMC Cancer; 2016 Nov; 16(1):855. PubMed ID: 27821098
[TBL] [Abstract][Full Text] [Related]
6. Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site.
Albino AP; Jaehne J; Altorki N; Blundell M; Urmacher C; Lauwers G; Niedzwiecki D; Kelsen DP
Eur J Surg Oncol; 1995 Feb; 21(1):56-60. PubMed ID: 7851555
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
Yoshioka T; Shien K; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Asano H; Soh J; Tsukuda K; Nagasaka T; Fujiwara T; Toyooka S
Cancer Sci; 2018 Apr; 109(4):1166-1176. PubMed ID: 29465762
[TBL] [Abstract][Full Text] [Related]
8. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
9. CDX-2 and HER-3 expression in canine gastric and colorectal adenocarcinomas.
Doster AR; Yhee JY; Kim JH; Im KS; Sur JH
J Comp Pathol; 2011 Jul; 145(1):12-9. PubMed ID: 21238975
[TBL] [Abstract][Full Text] [Related]
10. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma.
Ahmed A; Al-Tamimi DM
Libyan J Med; 2018 Dec; 13(1):1466573. PubMed ID: 29697008
[TBL] [Abstract][Full Text] [Related]
14. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
15. Expression and Content of Protein LC3B in Gastric Cancer Tissue, Relationship with Expression of mTOR, AMPK in Gastric Cancer Tissue and HER2 and PD-L1 Status of the Tumor.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Volkov MY; Kondakova IV
Bull Exp Biol Med; 2021 Dec; 172(2):202-205. PubMed ID: 34855092
[TBL] [Abstract][Full Text] [Related]
16. The HER-2/neu oncogene in tumors of the gastrointestinal tract.
Ross JS; McKenna BJ
Cancer Invest; 2001; 19(5):554-68. PubMed ID: 11458821
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
19. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.
Farzand S; Siddique T; Saba K; Bukhari MH
World J Gastroenterol; 2014 May; 20(19):5889-96. PubMed ID: 24914350
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
